The FDA’s Complete Response Letter to Summit Therapeutics offers a more detailed explanation for why ivonescimab was rejected in EGFR-mutated non-small cell lung cancer, and the message is broader than a single missed endpoint. Reviewers said the application did not provide substantial evidence of effectiveness or establish a positive benefit-risk profile, challenging both the relevance of the dataset to U.S. patients and the safety tradeoff behind the drug’s modest progression-free survival result.
That matters beyond Summit. Ivonescimab would have been the first PD-1/VEGF bispecific approved in the U.S. for this indication, and the rejection now sets a clearer regulatory threshold for other companies developing assets in the class, including BioNTech and partner Bristol Myers Squibb, plus Pfizer, Merck and AbbVie.
The Data
Summit had based its application on an improvement in progression-free survival from a Phase 3 study in EGFR-mutated NSCLC, but the trial did not show an overall survival benefit in this population. The company later submitted a post-hoc analysis in September to support overall survival, using longer follow-up, but the FDA dismissed that package as exploratory only.
The agency agreed that the progression-free survival endpoint was statistically significant, but said the effect size was “modest” in the context of an add-on to chemotherapy. The drug also did not show improvement in overall survival or overall response rate.
The more consequential issue may have been geography. According to the letter, 93% of the events supporting progression-free survival occurred in patients enrolled in China. The study was originally designed as a single-country trial in China and was not modified to include North American and European patients until May 2023. Because of that timing, the trial population remained heavily skewed toward Asia, and the FDA said applicability of the progression-free survival result to U.S. patients could not be determined.
Reviewers said the agency had warned Summit during meetings in March 2023 and again in May 2025 that this could become a problem. The letter also pointed to uneven data cutoff dates across regions. It said the differential cutoff dates appeared to reflect earlier termination of follow-up for patients enrolled in China compared with patients enrolled in North America and Europe, with clinical sites in China closing during 2025.
Safety And Benefit-Risk
The FDA also raised safety concerns tied to the biology of the regimen. In the letter, reviewers said the modest progression-free survival improvement had to be weighed against the added risk of serious immune-related toxicities and toxicities known to VEGF inhibition.
The agency did not provide detail in the letter on the possible safety risk, but its framing suggests the review was not simply about whether the efficacy package was incomplete. It was also about whether the extra toxicity burden was justified by the magnitude and quality of the observed benefit.
That distinction is important for the broader PD-1xVEGF field. A bispecific in this class may need more than numerical activity in a largely China-enrolled dataset; it may also need a cleaner demonstration that any added efficacy is clinically meaningful enough to offset combination-related risk.
What The FDA Wants Next
To address the deficiencies, FDA reviewers recommended a new adequate and controlled multi-regional clinical trial of ivonescimab in EGFR-mutated NSCLC. They said the study must show statistically significant and clinically meaningful improvement in overall survival, progression-free survival or another endpoint that measures clinical benefit. The reviewers also suggested Summit meet with the FDA before moving ahead with such a trial.
Summit licensed ivonescimab from Akeso, which has already secured approval in China for this indication and several others. The U.S. filing had drawn attention partly because strong Chinese data had led some to describe the asset as a potential challenger to Merck’s Keytruda after ivonescimab beat that drug in a head-to-head trial in China.
The new letter reframes the issue. The FDA is not disputing that the drug generated activity; it is saying the submitted evidence did not establish that the activity was sufficiently transferable, durable and favorable on benefit-risk terms for the U.S. market. For developers of PD-1xVEGF programs, that is a more demanding and more specific signal than a simple request for more follow-up.




